Please use this identifier to cite or link to this item:
Title: Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma.
Issue Date: 26-Nov-2018
Citation: BMC Pharmacol Toxicol.2018 Nov;(19)1:77
Abstract: Pazopanib is indicated in the first-line treatment of metastatic renal cell cancer (mRCC). The aim of this study was to review the efficacy, safety, and pharmacokinetics of pazopanib and see how these aspects are linked to clinical practice.
PMID: 30477570
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos
Hospitales > H. U. La Paz > Artículos

Files in This Item:
File Description SizeFormat 
PMC6258404.pdf710.31 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.